Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) was the recipient of some unusual options trading on Monday. Investors bought 6,088 put options on the company. This represents an increase of 1,469% compared to the typical daily volume of 388 put options.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Truist Financial cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price target on Fulcrum Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th. Leerink Partners lowered Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price on the stock. in a report on Tuesday, June 2nd. Finally, Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and an average target price of $8.20.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC traded up $0.06 during mid-day trading on Monday, reaching $3.79. 3,298,162 shares of the company’s stock were exchanged, compared to its average volume of 1,625,234. The firm has a market capitalization of $289.56 million, a price-to-earnings ratio of -3.14 and a beta of 3.05. Fulcrum Therapeutics has a twelve month low of $2.83 and a twelve month high of $15.74. The business’s fifty day moving average price is $3.67 and its 200-day moving average price is $6.43.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Analysts predict that Fulcrum Therapeutics will post -0.69 EPS for the current fiscal year.

Insider Buying and Selling

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total transaction of $65,700.00. Following the transaction, the director directly owned 10,927 shares in the company, valued at approximately $39,883.55. This represents a 62.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FULC. Deutsche Bank AG grew its stake in shares of Fulcrum Therapeutics by 0.6% in the 4th quarter. Deutsche Bank AG now owns 287,096 shares of the company’s stock valued at $3,247,000 after buying an additional 1,767 shares during the period. Intech Investment Management LLC increased its stake in shares of Fulcrum Therapeutics by 14.5% during the fourth quarter. Intech Investment Management LLC now owns 19,747 shares of the company’s stock worth $223,000 after buying an additional 2,503 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Fulcrum Therapeutics during the 4th quarter worth about $30,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Fulcrum Therapeutics by 25.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company’s stock valued at $124,000 after buying an additional 3,219 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Fulcrum Therapeutics during the 4th quarter worth approximately $39,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.